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Abstract 1 
Background.  Anterior compartment prolapse is the most common pelvic organ 2 
prolapse (POP) with a range of surgical treatment options available. 3 
Objectives. To compare the clinical and cost effectiveness of surgical treatments for the 4 
repair of anterior POP. 5 
Methods. We conducted a systematic review of randomised controlled trials (RCTs) 6 
comparing surgical treatments for women with POP. Network meta-analysis (NMA) was 7 
possible for anterior POP, same site recurrence outcome. A Markov model was used to 8 
compare the cost–utility of surgical treatments for the primary repair of anterior POP 9 
from a UK National Health Service perspective.  10 
Main results. We identified 27 eligible trials for the NMA involving eight surgical 11 
treatments tested on 3,194 women. Synthetic mesh was the most effective in preventing 12 
recurrence at the same site. There was no evidence to suggest a difference between 13 
synthetic non-absorbable mesh, synthetic partially absorbable mesh, and biological 14 
mesh. The cost-utility analysis which incorporated effectiveness, complications, and cost 15 
data found non-mesh repair to have the highest probability of being cost-effective. The 16 
conclusions were robust to model inputs including effectiveness, costs, and utility values. 17 
Conclusions. Anterior colporrhaphy augmented with mesh appeared to be cost-18 
ineffective in women requiring primary repair of anterior POP. There is a need for further 19 
research on long-term effectiveness and the safety of mesh products to establish their 20 
relative cost-effectiveness with a greater certainty. 21 
Keywords: pelvic organ prolapse, anterior prolapse, mesh, network meta-analysis, cost-22 
effectiveness, outcome research, National Institute of Health and Care Excellence. 23 
Tweetable abstract: New study finds mesh cost-ineffective in women with anterior 24 
pelvic organ prolapse 25 
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Introduction 1 
Anterior compartment prolapse is the most common pelvic organ prolapse (POP) with a 2 
lifetime risk of surgery estimated between 11-19%.1 Anterior POP is defined as the 3 
descent of the anterior vaginal wall.2 Treatments include conservative or surgical 4 
options, and depend on symptoms, POP degree, and patient preferences.3 5 
Anterior colporrhaphy (AC) is considered the standard surgical treatment but is 6 
associated with a significant rate of failure.4 Surgery with mesh augmentation was 7 
introduced to improve outcomes but there are safety concerns about its use and no data 8 
on long-term outcomes.1 Synthetic meshes may lead to chronic complications needing 9 
long-term management. To address these concerns NHS England set up the Mesh 10 
Working Group and an independent review of transvaginal mesh implants was 11 
undertaken in Scotland.5, 6 Mesh products have also been scrutinised by the European 12 
Commission (SCENIHR) and US Food and Drug Administration (FDA).7, 8 13 
The aim of this work was to evaluate which surgical procedures are the most clinically 14 
and cost-effective in women undergoing repair of anterior POP. This analysis was used 15 
to inform a national guideline on the management of urinary incontinence and POP in 16 
women, released by the National Institute for Health and Care Excellence (NICE) in 17 
England.9  18 
Methods 19 
Methods of the systematic review and network meta-analysis 20 
We carried out a systematic review to identify relevant randomised controlled trials 21 
(RCTs) using a predefined search strategy (see Appendix S1). The final search date 22 
was June 2018. A 10% random sample of the literature search results was screened by 23 
a second reviewer against inclusion criteria specified in the review protocol.9 24 
 
 
One reviewer extracted data from the eligible studies, including study characteristics, 1 
aspects of methodological quality, outcome data, and risk of bias, which were checked 2 
by a second reviewer.10  3 
RCTs on surgical procedures in women with predominantly anterior, primary or 4 
secondary repair were included. The critical outcomes in the systematic review were 5 
health-related quality of life (HRQoL), adverse events, and complications including 6 
recurrence of POP. The recurrence of anterior POP was the only dichotomous outcome 7 
that could be synthesised using network meta-analysis (NMA). Data was poorly reported 8 
for other outcomes and were insufficient to inform NMA.  9 
NMA combines direct and indirect evidence to estimate relative effects between all pairs 10 
of interventions in a network, even if some pairs of interventions have not been directly 11 
compared in head-to-head trials.11-14 Fixed and random effects NMA models (binomial 12 
likelihood and cloglog link) were fitted in a Bayesian framework, using WinBUGS 1.4.3.12, 13 
15 The goodness-of-fit of each model was assessed and the model with best fit was 14 
selected as the base-case NMA model. (See Appendix S2)  15 
Relative effects between surgical procedures were expressed as posterior median 16 
hazard ratios (HRs) with 95% credible intervals (CrIs). Surgical procedures were also 17 
ranked based on their effectiveness, with a rank of 1 representing the best procedure. 18 
Median ranks and 95% CrI are presented for each surgical procedure. 19 
The suitability of the consistency assumption was assessed by comparing the selected 20 
base-case NMA model to an ‘inconsistency’, or unrelated mean effects, model and by 21 
node-splitting.16-18 (See Appendix S2). 22 
Methods for the cost-effectiveness analysis 23 
We developed a de novo Markov model to estimate the cost-effectiveness of effective 24 
surgical procedures over 15 years in adult women who required surgical repair for 25 
primary anterior POP using the data obtained from the NMA (see Appendix S3). The 26 
model was run in yearly cycles and included the following health states: ‘well’ (i.e. 27 
 
 
successfully managed POP), ‘failure/recurrence’, and ‘complications’. The model 1 
considered only one recurrence following the primary repair given that few women have 2 
more than two repairs.19 3 
Clinical inputs 4 
The baseline risk of anatomical recurrence was estimated by combining the probability 5 
of surgically managed recurrence derived from a long-term naturalistic study with the 6 
probability of anatomical recurrence adjusted for the surgically managed recurrence that 7 
was derived from the AC arm of the RCT with the longest available follow-up amongst 8 
those included in the systematic review.19, 20  9 
This approach was used since the identified naturalistic studies focused only on 10 
surgically-managed recurrence and the effectiveness data estimated from the NMA were 11 
for anatomical recurrence. Identified long-term rates were used to estimate the annual 12 
probabilities of recurrence. Given the uncertainty about how the recurrence risk varies 13 
with time, a constant risk was modelled each year for the duration of the model. 14 
We applied the HRs from the NMA to the baseline risk for the reference surgical 15 
procedure (AC), to obtain absolute probabilities for all surgical treatments. Given that the 16 
follow-up times in RCTs included in the NMA were clustered around one to three years 17 
the estimated HRs of mesh procedures (versus AC) were applied during the first three 18 
years only. After the three years, the risk of recurrence in mesh groups was modelled to 19 
be the same as for women receiving AC only. 20 
The risk of surgically managed recurrence following a secondary repair was based on an 21 
observational cohort study.21 This study did not report the anatomical recurrence rate 22 
and so this was taken from a UK-based RCT.22 The annual probabilities were estimated 23 
as described above for the primary repair.  24 
The mortality rate from POP surgery is small (37 per 100,000 cases) and would only 25 
make a very small contribution to the health state utility loss because mortality is not 26 
expected to vary between surgical procedures and very few women choose to undergo 27 
 
 
further repairs following POP recurrence.23 Therefore mortality was not considered in the 1 
analysis.  2 
Complications 3 
Surgical complications other than those associated with the mesh itself were not 4 
deemed to vary much across arms and were excluded from the analysis. Surgical 5 
treatment with mesh is associated with various complications. Given the uncertainty 6 
about the long-term incidence of complications, only those assumed to have the greatest 7 
impact on HRQoL and costs, including mesh extrusion and pain, were modelled.  8 
Rates of mesh extrusion and pain were taken from cohort studies and were used to 9 
estimate the annual probabilities attached to the synthetic mesh repairs.24, 25 Since 10 
women continue to develop complications during long-term follow-up, the estimated 11 
annual probabilities were applied at each year for the duration of the model. 12 
It is not known what proportion of mesh complications, including mesh extrusion and 13 
pain, resolve over time. Based on GC expert opinion, the model assumed that most 14 
complications will resolve by year two and a small proportion of mesh complications 15 
(10%) will persist for the duration of the model. The complication data were insufficient to 16 
differentiate between different synthetic mesh types (non-absorbable and partially 17 
absorbable). 18 
The systematic review indicated that the risk of mesh extrusion was lower for biological 19 
mesh than for synthetic mesh.9 The risk ratio estimated from the systematic review was 20 
applied to the risk of mesh extrusion with synthetic mesh to estimate the annual risk of 21 
mesh extrusion associated with the biological mesh.9 However, given the lack of long-22 
term clinical data on pain complications associated with the biological mesh, the same 23 
rate as for synthetic mesh was used in the analysis. 24 
Cost data 25 
We adopted a UK NHS perspective and considered costs of surgical procedures, mesh 26 
products, conservative management, repeat surgery, and complication management.  27 
 
 
The repeat surgery cost was modelled as the average of surgical mesh and non-mesh 1 
procedure costs, and also an apical procedure cost as recurrent anterior vaginal wall 2 
POP could be associated with apical descent.  3 
The cost associated with conservative management was obtained from a UK-based 4 
RCT which included treatment with pelvic floor exercises, oestrogens and pessaries.26 It 5 
was assumed that only half of women experiencing recurrence would require treatment; 6 
symptoms in other women were not severe enough to require treatment for their POP.27  7 
The economic analysis also included complementary tests (blood tests and urea and 8 
electrolytes) and consultations that would typically be carried out before and after 9 
surgery.  10 
It was assumed that just over half of women with a mesh extrusion would require 11 
surgical revision, while for the rest treatment included topical oestrogens and close 12 
surveillance.24 Pain management included pharmacological treatments, vaginal 13 
oestrogen, dilators, psychosexual counselling, physiotherapy, or mesh removal. Costs 14 
associated with persistent mesh complications were modelled to be equivalent to the 15 
initial management cost. Therefore, the initial cost associated with a complication was 16 
apportioned over the time horizon of the model to approximate the annual cost 17 
associated with managing persistent mesh complications. 18 
Unit costs were derived from national sources expressed in 2016/17 prices.28-31 19 
Utility values 20 
In order to express outcomes in the form of quality-adjusted life years (QALYs), the 21 
health states of the economic model needed to be linked to appropriate utility scores. 22 
Utility values were required for active POP, resolved POP, recurrent POP, and 23 
complications. Utility estimates were derived from the published UK RCT that reported 24 
the EuroQol (EQ-5D-3L) utility scores, estimated using the UK Time Trade-Off Tariff.26 25 
 
 
Handling uncertainty 1 
To account for the uncertainty around the input parameter point estimates, a probabilistic 2 
analysis was undertaken, in which input parameters were assigned probabilistic 3 
distributions.32 Subsequently, 10,000 iterations were performed, each drawing random 4 
values out of the specified distributions. Mean costs, QALYs and the Net Monetary 5 
Benefit (NMB) for each surgical treatment were calculated by averaging across 10,000 6 
iterations. We conducted a full incremental analysis, reporting incremental cost-7 
effectiveness ratios (ICERs), interpreted as the additional expected cost per additional 8 
unit gain in utility for a surgical procedure compared with the previous non-dominated 9 
surgical procedure. We represented uncertainty in the optimal surgical procedure by 10 
estimating the probability of each surgical procedure being cost-effective at £20,000-11 
30,000 threshold values. A range of deterministic sensitivity analyses were undertaken. 12 
Table S1 (see Supplementary material) summarises all model inputs including clinical 13 
data inputs, cost data and utility estimates and evidence sources; and provides details 14 
on the types of distributions assigned to each. 15 
Results 16 
Results of the systematic review and NMA 17 
A total of 2,378 studies were identified in the literature searches with 27 trials (3,194 18 
participants) contributing data to the NMA outcome of same site recurrence (Figure 1). 19 
Insert Figure 1. 20 
Eight surgical procedures were included. One study was excluded from the NMA 21 
because treatments were not connected to the rest of the network.33, 34 A further study 22 
was excluded because the definition of recurrence was unclear.34 The resulting network 23 
of trials contributing data to the NMA is presented in Figure 2. (The details of the 24 
included studies in the NMA and the final data file used are presented in Table S2 and 25 
Table S3, respectively). 26 
 
 
Insert Figure 2. 1 
Approximately 30% of the included trials were assessed as being unclear or at high risk 2 
of selection bias, namely for allocation concealment and sequence generation. Not 3 
unexpectedly, the majority of trials (96%) were unclear or at high risk of performance 4 
bias for blinding, since blinding is more difficult to incorporate in trials of surgical 5 
procedures. Approximately 40% of the included trials were unclear or at high risk of 6 
attrition bias, reporting bias, and other biases.  7 
Each NMA model (fixed or random effects) was run until convergence was satisfactory; 8 
results were then based on a further sample of iterations on three separate chains. The 9 
random effects model had more favourable fit to the data, and so all further analyses are 10 
based on that model (τ=0.63, 95% CrI 0.38 to 0.97). (See Appendix S2). 11 
Table 1 reports the posterior median HRs and 95% CrIs for each surgical procedure 12 
relative to AC for recurrence outcome. Paravaginal repair & synthetic non-absorbable 13 
mesh had the lowest HRs (best) of recurrence when compared with AC (HR 0.25, 95% 14 
CrI 0.04-1.26). However, this procedure was tested on small numbers of women across 15 
studies and the result was characterised by considerable uncertainty, as indicated by 16 
wide 95% CrI.  17 
Insert Table 1. 18 
There was evidence to suggest that AC with synthetic non-absorbable mesh (HR 0.38, 19 
95% CrI 0.24-0.59), AC with synthetic partially absorbable mesh (HR 0.27, 95% CrI 20 
0.11-0.62), and AC with biological mesh (HR 0.44, 95% CrI 0.26-0.73) were more 21 
effective when compared with AC alone. However, there was no difference between 22 
various mesh types.  23 
The treatment with the best posterior median rank were AC with synthetic partially 24 
absorbable mesh (1st, 95% CrI 1st to 5th) followed by paravaginal repair with synthetic 25 
non-absorbable mesh (2nd, 95% CrI 1st to 7th), AC with synthetic non-absorbable mesh 26 
(3rd, 95% CrI 1st to 6th), AC with biological mesh (4th, 95% CrI 1st to 6th), AC with synthetic 27 
 
 
absorbable mesh, paravaginal repair with biological mesh (6th, 95% CrI 2nd to 8th), and 1 
AC only (7th, 95% CrI 5th to 8th).  2 
No evidence of inconsistency between direct and indirect estimates was identified. (See 3 
Appendix S3) 4 
Results of the cost-effectiveness analysis 5 
Table 2 shows the expected total costs and QALYs for each surgical procedure. It also 6 
provides the results of the incremental analysis, the mean NMB of each procedure at the 7 
£20,000 per QALY threshold, the ranking of procedures by NMB, and also the probability 8 
of each surgical procedure being cost effective at threshold values. Surgical procedures 9 
are ordered by increasing expected total cost. All treatments were dominated by AC, 10 
which was more effective in terms of increased QALYs and less expensive than all other 11 
surgical procedures (Table 2). AC with synthetic non-absorbable mesh had the highest 12 
expected cost and the lowest expected QALYs.  13 
Insert Table 2. 14 
The expected NMB at a £20,000 threshold is highest for AC (£189,156), followed by AC 15 
with biological mesh (£187,869), AC with synthetic partially absorbable mesh 16 
(£186,337), and lowest for AC with synthetic non-absorbable mesh (£186,306). Also, AC 17 
has the highest probability of being cost-effective (Table 2). As the threshold increases, 18 
the probability of AC with biological mesh increases but this probability never exceeds 19 
26%. 20 
Sensitivity analyses 21 
Results were robust to model inputs including effectiveness, costs, and utilities. Under all 22 
scenarios examined AC remained the preferred surgical procedure. For example, in the 23 
base-case analysis, it was assumed that treatment effectiveness at four years onwards 24 
for mesh procedures will be the same as for AC. Assuming that treatment effectiveness 25 
is sustained for the duration of the model did not change the conclusions. 26 
 
 
Most mesh extrusion cases happened in the first year with the risk decreasing over 1 
time.24 This was derived from a small study and there were little data on the frequency of 2 
mesh complications occurring in the long-term; however, the GC were aware of women 3 
who experienced mesh complications many years after mesh insertion. Nevertheless, 4 
the mesh was cost-ineffective even when we only used the available rates of mesh 5 
complications. 6 
The results of all deterministic sensitivity analyses are presented in Table S4 (see 7 
Supplementary Information).  8 
Discussion 9 
Main findings 10 
Overall, the results from the NMA indicate that the use of mesh is more successful than 11 
non-mesh surgical procedures in preventing anterior POP recurrence. The cost-12 
effectiveness analysis attempted to bring together the information on clinical 13 
effectiveness, complications, and costs, and suggested that, although mesh is more 14 
effective, it causes more complications and is cost-ineffective for women who require 15 
primary repair of anterior POP. It should be noted that the long term safety of mesh is 16 
unclear and there is considerable uncertainty in this model input. Nevertheless, overall 17 
the conclusions were robust to changes in this and other model inputs.  18 
Strengths and limitations 19 
To our knowledge this is the first urogynecologic NMA to compare multiple competing 20 
treatments for POP in a cost-utility analysis. We conducted a detailed search, and took 21 
considerable effort to include all available RCT data. We synthesised the effectiveness 22 
data from multiple RCTs using NMA methodology, and, where possible, the long-term 23 
baseline risks and the incidence rates of complications were obtained from cohort 24 
studies with the longest available follow-up.  25 
 
 
Despite robust methodology, not all trials provided data on key outcomes and this is a 1 
limitation of the study. Although it could be argued that surgically managed recurrence is 2 
a more important efficacy measure, there were insufficient data to allow synthesis of trial 3 
data on this outcome using NMA methodology.  4 
The length of follow-up in the RCTs informing the NMA was clustered around 12 to 36 5 
months and the cost-effectiveness analysis was confined to short-term effectiveness. 6 
Given the uncertainty surrounding the long-term effects associated with mesh 7 
procedures, it was conservatively modelled that treatment effectiveness at four years 8 
onwards for mesh procedures will be the same as for non-mesh procedure. This is in 9 
keeping  with the review of observational studies which suggest that the long-term 10 
recurrence rates following mesh surgery and non-mesh surgery were nearly identical.9 11 
Complication rates were poorly reported; therefore safety assessment was limited to 12 
data from single studies and at best provides only proxies for serious mesh 13 
complications. Despite this limitation, the conclusions were robust to changes in 14 
complication rates. 15 
It was recognised that POP procedures may be associated with a number of other 16 
complications. For example, de novo stress urinary incontinence (SUI) has been 17 
recognised as an important complication. However, the rate of SUI is similar following 18 
mesh and non-mesh surgery.9 The risk of urge incontinence (UUI) is higher following 19 
mesh surgery.9 However, the majority of UUI cases are successfully managed with low-20 
cost anticholinergic drugs and only a small proportion of women require treatment with 21 
higher-cost botulinum toxin. Similarly, in most cases constipation is easily managed with 22 
low-cost laxatives. Although, women who have obstructed defecation may require more 23 
intensive management, the rate of constipation is higher following mesh surgery and the 24 
exclusion of constipation only underestimated the cost-effectiveness of non-mesh 25 
surgery.9 The management of dyspareunia is partially captured by considering pain 26 
complications and since the rate of dyspareunia is higher in the mesh surgery, its 27 
omission only underestimated the cost-effectiveness of non-mesh surgery.9  28 
 
 
Another limitation of the study is that the literature search is over a year old. However, a 1 
literature search on PubMed (conducted April 2019) failed to identify any relevant new 2 
RCTs. Also, the GC were not aware of any relevant recently published RCTs. 3 
Interpretation 4 
Our finding that AC augmented with mesh is cost-ineffective is in line with current 5 
thinking among healthcare professionals. Even though the effectiveness data favour 6 
mesh, it is associated with an increased risk of complications. The cost-effectiveness 7 
analysis confirmed that mesh complications have a longer-term impact on women, and 8 
also on healthcare resources. It is worth pointing out that the clinical effectiveness plays 9 
a lesser role in the cost-effectiveness estimate since the probability of surgically 10 
managed recurrence is low and a large proportion of women are asymptomatic following 11 
recurrence. 12 
Our findings are consistent with a previous UK analysis which also found mesh 13 
augmentation to be cost-ineffective.35 The findings of a second economic evaluation 14 
were inconclusive, however the results are not directly comparable because they 15 
included women with AC and/or posterior colporrhaphy.22  16 
Conclusions 17 
Overall the analysis indicated that mesh was cost-ineffective in the primary repair of 18 
anterior POP, and, despite little long-term evidence on the efficacy and complications, 19 
our findings were robust. As a result, the NICE guideline recommended that mesh be 20 
considered only in recurrent anterior POP if apical support is adequate or an abdominal 21 
approach is contraindicated, after regional multidisciplinary team review and a detailed 22 
discussion with the woman about the risks of mesh insertion. 23 
Given the safety concerns associated with mesh products, future research may be 24 
unethical to answer this question with more certainty. However, as recommended in the 25 
NICE guideline, a national data registry would provide a better picture of long-term mesh 26 
complications, enable a more definite assessment of the cost-effectiveness of mesh 27 
 
 
procedures, and help identify clinically important subgroups where a mesh procedure 1 
may be an option. In the meantime, the data from this analysis should preclude the use 2 
of mesh products in women who require primary anterior POP repair. 3 
  4 
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TABLES AND FIGURES 1 
Figure 1. Preferred Reporting Items for Systematic reviews and Meta-Analyses 2 
(PRISMA) flowchart. 3 
Figure 2. Network diagram of all studies included in the analysis of recurrence at the 4 
same site in women undergoing primary repair of anterior POP. 5 
 6 
Table 1. Posterior median hazard ratios and 95% credible intervals for recurrence at the 7 
same site for every surgical procedure compared with each other in women with anterior 8 
POP. 9 
Table 2. Cost-effectiveness of surgical procedures for women with anterior POP; results 10 
of probabilistic analysis. Mean values for a cohort of 100 women over 15 years. 11 
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Table 1. Posterior median hazard ratios and 95% CrI for recurrence at the same site for every surgical procedure compared with each other in women with 1 
anterior POP. 2 
 
Paravaginal repair 
& biological mesh 
- - - - - - 
0.84  
(0.17, 4.22) 
0.72  
(0.05, 9.90) 
Paravaginal 
defect repair 
(abdominal) 
- - - - - - 
3.44  
(0.66, 19.17) 
4.79  
(0.32, 73.79) 
Paravaginal repair & 
synthetic non-
absorbable mesh 
- - - - 
0.25  
(0.04, 1.37) 
0.95  
(0.12, 7.42) 
1.31  
(0.27, 6.58) 
0.28  
(0.03, 2.41) 
AC & synthetic 
absorbable mesh 
- - - 
0.88  
(0.20, 3.96) 
3.17  
(0.56, 18.37) 
4.36  
(0.45, 44.13) 
0.92  
(0.14, 5.99) 
3.31  
(0.67, 17.30) 
AC & synthetic 
partially absorbable 
mesh1 
- 
0.82  
(0.17, 4.01) 
0.25  
(0.08, 0.72) 
1.91  
(0.39, 9.68) 
2.66  
(0.30, 24.16) 
0.56  
(0.09, 3.15) 
2.01  
(0.46, 8.98) 
0.61  
(0.22, 1.63) 
AC & 
biological 
mesh1 
0.85  
(0.27, 2.46) 
0.48  
(0.26, 0.89) 
2.19  
(0.46, 10.88) 
3.04  
(0.35, 27.35) 
0.64  
(0.11, 3.58) 
2.31  
(0.55, 10.13) 
0.70  
(0.28, 1.71) 
1.15  
(0.63, 2.13) 
AC & synthetic 
non-absorbable 
mesh1 
0.36  
(0.20, 0.60) 
0.84  
(0.18, 3.82) 
1.17  
(0.14, 9.80) 
0.25  
(0.04, 1.26) 
0.89  
(0.22, 3.52) 
0.27  
(0.11, 0.62) 
0.44  
(0.26, 0.73) 
0.38  
(0.24, 0.59) 
AC 
 3 
1 indicates that the surgical procedure was included in the cost-effectiveness analysis 4 
AC: anterior colporrhaphy; CrI: credible intervals; HR: Hazard ratio; NMA: network meta-analysis, POP: pelvic organ prolapse 5 
Note: Lower diagonal: Posterior median HRs and 95% CrIs from NMA. HRs lower than 1 favour the column defining treatment, HRs higher than 1 favour the row defining treatment. Upper 6 
diagonal: HR and 95% CrIs from direct pairwise meta-analysis. HRs lower than 1 favour the row defining treatment, HRs higher than 1 favour the column defining treatment. Bolded cells indicate 7 
effects which do not cross the line of no treatment effect. 8 
 
 
 
Table 2. Cost-effectiveness of surgical procedures for adult women with anterior POP; results of probabilistic analysis. Mean values for a cohort of 100 1 
women over 15 years. 2 
Surgical procedure Mean 
QALYs1 
Mean total 
costs (£) 
Incremental analysis & 
ICERs (£/QALY) 
Mean NMB 
(£) 
Ranking by 
highest NMB 
Probability of being cost-effective at 
a £20,000-30,000/QALY threshold 
AC only 9.667  £4,192  Dominant  £189,156  1 0.695-0.676 
AC with biological mesh 9.641  £4,959  Dominated  £187,869  2 0.177-0.211 
AC with synthetic partially 
absorbable mesh 
9.557  £4,809  Dominated  £186,337  3 0.098-0.091 
AC with synthetic non- 
absorbable mesh 
9.558  £4,859  Dominated  £186,306  4 0.030-0.022 
 3 
1 Procedures ranked from the most to the least effective according to the number of QALYs 4 
AC: anterior colporrhaphy, ICER: incremental cost-effectiveness ratio, NMB: net monetary benefit, estimated using a willingness to pay £20,000/QALY, POP: pelvic organ prolapse, QALY: quality 5 
adjusted life years 6 
 7 
